Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of REGN7508 in healthy adults
NCT05603195Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2023
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of REGN7508 in venous thromboembolism (VTE) and thrombosis (10 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidences of treatment-emergent adverse events up to 36 days and Severity of treatment-emergent adverse events up to 36 days. Started Jan 2023; status: completed.
02
Drugs
REGN7508
03
Conditions
venous thromboembolism (VTE)thrombosis
Beyond the preview
Go deeper on NCT05603195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603195.